Drug Trial Radar · NCT03290235
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
Last checked: Nov 19, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,500
Planned (sponsor's estimate)
Start
Mar 1, 2017
Primary completion
Oct 2020
Study completion Sep 2021
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 42 months, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period 2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.
Conditions
- Growth Retardation
Interventions
PEG-somatropinDrug
Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ht SDSca (Height standard deviation score for chronological age)Time frame: Baseline, every 13 weeks until 130 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TongJi hospital affiliated to TongJi medical college of HuaZhong university of Science & Teconology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.